🇺🇸 FDA
Patent

US 10730949

Method of treating PVNS with anti-CSF1R antibodies

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 10730949 (Method of treating PVNS with anti-CSF1R antibodies) held by Five Prime Therapeutics, Inc. expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Five Prime Therapeutics, Inc.
Grant date
Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61K, A61K2039/505, A61K2039/545, A61P, A61P19/02